title: Structural characteristics of repair tissue of cricoid cartilage defects treated with recombinant human bone morphogenetic protein-2.
abstract: We examined the structural characteristics of repair tissue induced by recombinant human bone morphogenetic protein-2 in a rabbit model of laryngotracheal reconstruction. Twenty-four New Zealand White rabbits were randomly divided into four groups of six rabbits. Two groups were treated with recombinant human bone morphogenetic protein-2 delivered on an absorbable collagen sponge, while two groups were used as controls. Rabbits were euthanized at 1 and 4 weeks after surgery. The larynx was removed, fixed, and sectioned. The sections were stained with hematoxylin-eosin, safranine O/fast green, and immunostained with an antibody for tissue inhibitor of metalloproteinases-1. In rabbits treated with bone morphogenetic protein-2, the defects were filled with new cartilage and bone at 4 weeks after surgery. There were no discontinuities or gaps at the margins of the cartilage defects. Proteoglycans were synthesized in new cartilage in rabbits treated with bone morphogenetic protein-2, and were present 4 weeks after surgery. The general aspects of the vascular pattern and the pattern of tissue inhibitor of metalloproteinases-1 expression were similar in control and treated rabbits, both 1 week and 4 weeks after surgery. The repair tissue induced by recombinant human bone morphogenetic protein-2 consisted of new cartilage and bone perfectly integrated with host tissue at the site of the cricoid cartilage defects. This new cartilage was able to mature and produce proteoglycans.
authors.affiliation: Department of Otorhinolaryngology, Huddinge University Hospital, Karolinska Institutet, Huddinge, Sweden. tcacencu@yahoo.co.uk
authors.forename: Ion
authors.initials: I
authors.lastname: Tcacencu
authors.forename: Bengt
authors.initials: B
authors.lastname: Carlsöö
authors.forename: Pontus
authors.initials: P
authors.lastname: Stierna
mesh_terms: D000818:Animals; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins / Q000494:pharmacology*; D001861:Bone Regeneration / Q000187:drug effects; D003413:Cricoid Cartilage / Q000187:drug effects* / Q000293:injuries / Q000503:physiopathology; D006133:Growth Substances / Q000494:pharmacology*; D006801:Humans; D008297:Male; D023421:Models, Animal; D018919:Neovascularization, Physiologic / Q000502:physiology; D011509:Proteoglycans / Q000032:analysis / Q000096:biosynthesis; D011817:Rabbits; D011994:Recombinant Proteins; D012038:Regeneration / Q000187:drug effects*; D019715:Tissue Inhibitor of Metalloproteinase-1 / Q000096:biosynthesis; D016212:Transforming Growth Factor beta / Q000494:pharmacology*; D014945:Wound Healing / Q000187:drug effects*
chemical_list: C525718:BMP2 protein, human; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins; D006133:Growth Substances; D011509:Proteoglycans; D011994:Recombinant Proteins; D019715:Tissue Inhibitor of Metalloproteinase-1; D016212:Transforming Growth Factor beta; C499469:recombinant human bone morphogenetic protein-2